|
ES2205018T3
(es)
*
|
1995-02-24 |
2004-05-01 |
Stuart Weg |
Administracion de ketamina para destoxificacion.
|
|
GB0009469D0
(en)
*
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formalities for use in inhaler devices
|
|
US20050148673A1
(en)
|
2002-07-11 |
2005-07-07 |
Harbut Ronald E. |
Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
|
|
CA2529857A1
(en)
|
2002-07-30 |
2004-02-05 |
Peter Migaly |
Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
|
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
NZ540282A
(en)
*
|
2002-11-18 |
2008-06-30 |
Yaupon Therapeutics Inc |
Analgesic uses of norketamine and ketamine/norketamine prodrugs
|
|
US10172810B2
(en)
|
2003-02-24 |
2019-01-08 |
Pharmaceutical Productions, Inc. |
Transmucosal ketamine delivery composition
|
|
WO2004076675A2
(en)
|
2003-02-26 |
2004-09-10 |
Johns Hopkins University |
Glutamate transport modulatory compounds and methods
|
|
EP1613324A2
(en)
|
2003-04-14 |
2006-01-11 |
Pain Therapeutics, Inc. |
Methods for the treatment of pain comprising opioid antagonists
|
|
CA2563707A1
(en)
|
2004-04-20 |
2005-11-03 |
Pfizer Inc. |
Method of treating neuropathic pain using a crth2 receptor antagonsit
|
|
EP1799264A2
(en)
|
2004-10-08 |
2007-06-27 |
Neuromolecular Pharmaceuticals Inc |
Methods and compositions for treating migraine pain
|
|
WO2006069293A2
(en)
|
2004-12-22 |
2006-06-29 |
Friedman Robert S |
Composition comprising n-acetylcysteine and further pain or anti- inflamm medications
|
|
RU2007132865A
(ru)
|
2005-03-01 |
2009-03-10 |
Пфайзер Лимитед (GB) |
Применение ингибиторов pde7 для лечения невропатической боли
|
|
CN101155548A
(zh)
|
2005-03-04 |
2008-04-02 |
曼提斯库拉Ehf.公司 |
评估神经病症的方法和系统
|
|
EP1874282B1
(en)
|
2005-04-06 |
2010-09-15 |
Adamas Pharmaceuticals, Inc. |
Methods and compositions for treatment of cns disorders
|
|
GB0523031D0
(en)
*
|
2005-11-11 |
2005-12-21 |
Yaupon Therapeutics |
Enhancement of morphine analgesia by s(-)-norketamine
|
|
WO2007076371A2
(en)
|
2005-12-19 |
2007-07-05 |
Pharmain Corporation |
Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
|
|
AU2007229866A1
(en)
|
2006-03-22 |
2007-10-04 |
Mount Sinai School Of Medicine |
Intranasal administration of ketamine to treat depression
|
|
RU2008150624A
(ru)
|
2006-05-22 |
2010-06-27 |
Ванда Фармасьютиклз, Инк. (Us) |
Лечение депрессивных расстройств
|
|
EP1902733A1
(en)
|
2006-09-19 |
2008-03-26 |
Laboratorios Del Dr. Esteve, S.A. |
Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
|
|
CA2677219A1
(en)
|
2007-02-01 |
2009-01-29 |
Alan I. Green |
Combinations of dopamine d2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade
|
|
DE102007009888A1
(de)
|
2007-02-28 |
2008-09-04 |
Hermann, Holger Lars, Dr. |
Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
|
|
HUE031070T2
(en)
|
2007-03-15 |
2017-06-28 |
Auspex Pharmaceuticals Inc |
Deuterated d9-venlafaxine
|
|
WO2008141057A1
(en)
|
2007-05-08 |
2008-11-20 |
Auspex Pharmaceuticals, Inc. |
Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea
|
|
US20090004281A1
(en)
|
2007-06-26 |
2009-01-01 |
Biovail Laboratories International S.R.L. |
Multiparticulate osmotic delivery system
|
|
WO2009000038A1
(en)
|
2007-06-28 |
2008-12-31 |
Cnsbio Pty Ltd |
Combination methods and compositions for treatment of neuropathic pain
|
|
EP2178584A2
(en)
|
2007-07-26 |
2010-04-28 |
Entra Pharmaceuticals Inc. |
Skin-patch pump comprising a changing-volume electrochemical actuator
|
|
EP2184986A4
(en)
|
2007-08-06 |
2010-12-15 |
Trinity Lab Inc |
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC PAIN AND PAIN RELATING TO NEUROPATHY
|
|
AU2008302079A1
(en)
|
2007-09-21 |
2009-03-26 |
Acadia Pharmaceuticals, Inc. |
Co-administration of pimavanserin with other agents
|
|
WO2009082039A1
(en)
|
2007-12-26 |
2009-07-02 |
Eisai R & D Management Co., Ltd. |
Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
|
|
US20090198145A1
(en)
|
2008-02-06 |
2009-08-06 |
Chow Harrison |
Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
|
|
US20140037718A1
(en)
|
2009-03-06 |
2014-02-06 |
George W. Lutz |
Transdermal pain gel
|
|
GB0908129D0
(en)
*
|
2009-05-12 |
2009-06-24 |
Innovata Ltd |
Composition
|
|
US20120225949A1
(en)
|
2009-08-14 |
2012-09-06 |
Demitri Papalos |
Compositions and methods for treating bipolar disorder
|
|
NZ599594A
(en)
|
2009-10-30 |
2014-06-27 |
Ix Biopharma Ltd |
Fast dissolving solid dosage form
|
|
CA2786380C
(en)
|
2010-01-18 |
2020-07-14 |
Elminda Ltd. |
Method and system for weighted analysis of neurophysiological data
|
|
WO2013003669A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of South Florida |
Compositions, methods of use, and methods of treatment
|
|
JP2015501652A
(ja)
|
2011-12-14 |
2015-01-19 |
アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ |
Ｇａｂｒ−ａ２診断
|
|
US20130236573A1
(en)
*
|
2012-03-12 |
2013-09-12 |
Janssen Pharmaceutica Nv |
Esketamine for the treatment of treatment-refractory or treatment-resistant depression
|
|
WO2013149102A1
(en)
|
2012-03-30 |
2013-10-03 |
The General Hospital Corporation |
Compositions comprising scopolamine and ketamine in the treatment of depression
|
|
US20120323214A1
(en)
|
2012-05-16 |
2012-12-20 |
Totada R Shantha |
Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis
|
|
WO2014020155A1
(en)
|
2012-08-02 |
2014-02-06 |
Clinpharm Reform Gmbh |
Oral transmucosal adminstration forms of s-ketamine
|
|
EP2887930A4
(en)
|
2012-08-23 |
2016-03-23 |
Stuart L Weg |
ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE
|
|
US8974365B2
(en)
|
2012-11-25 |
2015-03-10 |
Steven Richard Devore Best |
Treatment of thalamocortical dysrhythmia
|
|
US9868707B2
(en)
|
2012-12-20 |
2018-01-16 |
Sanford-Burnham Medical Research Institute |
Small molecule agonists of neurotensin receptor 1
|
|
MX371392B
(es)
|
2013-03-15 |
2020-01-28 |
Janssen Pharmaceutica Nv |
Composicion farmaceutica de clorhidrato de s-ketamina.
|
|
US20140275277A1
(en)
|
2013-03-15 |
2014-09-18 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition of s-ketamine hydrochloride
|
|
MX2015013845A
(es)
|
2013-04-01 |
2016-05-09 |
Pulmatrix Inc |
Polvos secos de tiotropio.
|
|
US9913803B2
(en)
|
2013-08-26 |
2018-03-13 |
Amorsa Therapeutics, Inc. |
Single-layer oral dose of neuro-attenuating ketamine
|
|
ES2897453T3
(es)
|
2013-09-13 |
2022-03-01 |
Univ Chiba Nat Univ Corp |
Aplicación de R-ketamina y sal de la misma como productos farmacéuticos
|
|
WO2015108985A1
(en)
|
2014-01-14 |
2015-07-23 |
Children's Hospital Medical Center |
Compositions comprising ketamine for treating an autism spectrum disorder
|
|
DK3131533T3
(da)
|
2014-04-17 |
2019-09-16 |
Develco Pharma Schweiz Ag |
Oral doseringsform for ketamin
|
|
CN106659762A
(zh)
|
2014-05-06 |
2017-05-10 |
西北大学 |
Nmdar调节化合物的组合
|
|
US11207316B2
(en)
|
2014-05-30 |
2021-12-28 |
West Virginia University |
Ketamine or dextromethorphan formulations and methods of use
|
|
WO2016007617A2
(en)
|
2014-07-09 |
2016-01-14 |
Novotec Consulting, Llc. |
Pharmaceutical compounding kit
|
|
EP3179993B1
(en)
|
2014-08-13 |
2021-01-20 |
Janssen Pharmaceutica NV |
Esketamine for use in a method for the treatment of depression
|
|
CA2961208A1
(en)
|
2014-09-15 |
2016-03-24 |
Janssen Pharmaceutica Nv |
Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
|
|
EP3209330B1
(en)
|
2014-10-07 |
2022-02-23 |
AI Therapeutics, Inc. |
An inhalable sirolimus formulation for the treatment of pulmonary hypertension
|
|
DK3215147T3
(da)
|
2014-11-04 |
2024-04-02 |
Acadia Pharm Inc |
Neurodæmpende norketamin-forbindelser og fremgangsmåder
|
|
CA2970065A1
(en)
|
2014-12-08 |
2016-06-16 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
|
US20180015054A1
(en)
|
2014-12-31 |
2018-01-18 |
Icahn School Of Medicine At Mount Sinai |
Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium
|
|
WO2016112467A1
(en)
|
2015-01-15 |
2016-07-21 |
Centre For Addiction And Mental Health |
Peripheral measure of central brain inflammation, markers therefor and uses thereof
|
|
EP3085366A1
(en)
|
2015-04-22 |
2016-10-26 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
|
|
US20160332962A1
(en)
|
2015-05-13 |
2016-11-17 |
Janssen Pharmaceutica Nv |
(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
|
|
WO2016186968A1
(en)
|
2015-05-15 |
2016-11-24 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for treating motor disorders
|
|
US20160338977A1
(en)
|
2015-05-20 |
2016-11-24 |
Janssen Pharmaceutica Nv |
Methods and kits for treating depression
|
|
EP3307910B1
(en)
|
2015-06-12 |
2024-10-30 |
Indiana University Research & Technology Corporation |
Predicting suicidality using a combined genomic and clinical risk assessment
|
|
US11191734B2
(en)
|
2015-06-27 |
2021-12-07 |
Shenox Pharmaceuticals, Llc |
Ketamine transdermal delivery system
|
|
CN106562952B
(zh)
*
|
2015-10-09 |
2020-06-09 |
江阴安博生物医药有限公司 |
氯胺酮在治疗重性抑郁障碍中的应用
|
|
KR20180102052A
(ko)
|
2015-10-16 |
2018-09-14 |
노오쓰웨스턴 유니버시티 |
조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
|
|
US10881637B2
(en)
|
2015-11-17 |
2021-01-05 |
Atlee Solomon |
Intranasal and transdermal administration of kappa-opioid-receptor agonists: salvinorin A for the treatment of neuropsychiatric and addictive disorders
|
|
EP3377050A4
(en)
|
2015-11-17 |
2019-11-20 |
The Trustees of Columbia University in the City of New York |
PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS
|
|
US20180296478A1
(en)
|
2016-02-12 |
2018-10-18 |
Synergistic Therapeutics, Llc |
Sublingual antidepressant and antianxiety tablet
|
|
US20180042936A1
(en)
|
2016-03-18 |
2018-02-15 |
Genomind, Inc. |
Maintenance therapy using tianeptine
|
|
WO2017165877A1
(en)
|
2016-03-25 |
2017-09-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post traumatic stress disorders
|
|
JP6967532B2
(ja)
|
2016-05-25 |
2021-11-17 |
ナショナル ヘルス リサーチ インスティテューツNational Health Research Institutes |
付加的抗うつ剤組成物及びその使用方法
|
|
EP3491014B1
(en)
|
2016-07-28 |
2023-04-05 |
Regeneron Pharmaceuticals, Inc. |
Allele-specific primer or probe hybridized to a nucleic acid molecule encoding a gpr156 variant
|
|
US10792253B2
(en)
|
2016-08-05 |
2020-10-06 |
Shin Nippon Biomedical Laboratories, Ltd. |
Pharmaceutical compositions
|
|
US20180064655A1
(en)
|
2016-09-06 |
2018-03-08 |
Steven Sounyoung Yu |
Hydroxynorketamine Transdermal Patch
|
|
US10596378B2
(en)
|
2016-10-18 |
2020-03-24 |
Joseph Rustick |
Method for treatment of depression using synaptic pathway training
|
|
US10905897B2
(en)
|
2016-10-20 |
2021-02-02 |
Neuro-Laser Foundation, Inc. |
Synergistic treatment methodologies using light therapy
|
|
CN110167541A
(zh)
|
2016-10-27 |
2019-08-23 |
国立大学法人千叶大学 |
(s)-去甲氯胺酮及其盐作为药物的应用
|
|
US20180177744A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
|
|
US20180177743A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain using racemic mixture of s-ketamine and r-ketamine
|
|
US20200030251A1
(en)
|
2017-04-20 |
2020-01-30 |
Guangzhou Dazhou Biomedicine Ltd. |
Transdermal drug delivery system for ketamine
|
|
CA3105451A1
(en)
|
2017-05-12 |
2018-11-15 |
Indiana University Research And Technology Corporation |
Precision medicine for treating and preventing suicidality
|
|
CA3064846A1
(en)
|
2017-05-25 |
2018-11-29 |
Glytech, Llc |
Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders
|
|
DE102017112527B4
(de)
|
2017-06-07 |
2019-01-03 |
Lts Lohmann Therapie-Systeme Ag |
Schnell zerfallende Schaumwafer mit hohem Flächengewicht
|
|
WO2018234568A2
(en)
|
2017-06-23 |
2018-12-27 |
Develco Pharma Schweiz Ag |
Hydroxynorketamine for the use in the treatment of depression
|
|
EP3668490A4
(en)
|
2017-08-20 |
2021-06-09 |
Formulex Pharma Innovations Ltd. |
Dry powder compositions for intranasal delivery
|
|
CA3076103A1
(en)
|
2017-09-25 |
2019-03-28 |
Small Pharma Ltd |
Solid oral dosage forms of ketamine derivatives
|
|
JP7265990B2
(ja)
|
2017-09-27 |
2023-04-27 |
国立大学法人千葉大学 |
神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
|
|
US12090123B2
(en)
|
2017-10-10 |
2024-09-17 |
Douglas Pharmaceuticals Ltd. |
Extended release pharmaceutical formulation
|
|
AU2018351515A1
(en)
|
2017-10-19 |
2020-05-21 |
Eleusis Health Solutions Us, Inc. |
Methods and systems for enhancing safety of psychedelic drug therapies
|
|
WO2019094757A1
(en)
|
2017-11-09 |
2019-05-16 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders in females
|
|
US20200384188A1
(en)
|
2017-11-14 |
2020-12-10 |
Bexson Biomedical, Inc. |
Systems, devices, formulations and methods for controlled drug delivery
|
|
DE102017129012A1
(de)
|
2017-12-06 |
2019-06-06 |
Lts Lohmann Therapie-Systeme Ag |
Oraler Dünnfilm mit hoher Wirkstoffbeladung
|
|
BR112020012473A2
(pt)
|
2017-12-22 |
2020-11-24 |
Janssen Pharmaceuticals, Inc. |
escetamina para o tratamento da depressão
|
|
PT3505157T
(pt)
|
2017-12-29 |
2022-02-18 |
Celon Pharma Sa |
Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento
|
|
RU2756512C1
(ru)
|
2018-01-10 |
2021-10-01 |
ЭксДабл-ЮФАРМА ЛТД. |
Пролекарства кетамина, его композиции и применения
|
|
WO2019164861A1
(en)
|
2018-02-21 |
2019-08-29 |
AI Therapeutics, Inc. |
Combination therapy with apilimod and glutamatergic agents
|
|
MX2020009668A
(es)
|
2018-03-16 |
2021-01-08 |
Intra Cellular Therapies Inc |
Métodos novedosos.
|
|
EP3761970A4
(en)
|
2018-03-26 |
2022-06-08 |
Cellix Bio Private Limited |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
|
|
US20230390385A1
(en)
|
2018-04-11 |
2023-12-07 |
Fred M. COWAN |
Compositions and Methods for Prevention and Treatment of Immune Complex Disease
|
|
JP2021523228A
(ja)
|
2018-05-04 |
2021-09-02 |
パーセプション ニューロサイエンス，インコーポレイティド |
物質乱用の治療方法
|
|
CN112469396A
(zh)
|
2018-05-31 |
2021-03-09 |
昆士兰大学 |
核壳聚合物纳米颗粒
|
|
GB201809976D0
(en)
|
2018-06-18 |
2018-08-01 |
Neurocentrx Pharma Ltd |
Novel formulations
|
|
CN114983979A
(zh)
|
2018-06-27 |
2022-09-02 |
比奥克斯塞尔医疗股份有限公司 |
含右美托咪定的膜制剂及其制造方法
|
|
CA3103440A1
(en)
|
2018-06-27 |
2020-01-02 |
Clexio Biosciences Ltd. |
Method of treating major depressive disorder
|
|
CN112512509A
(zh)
|
2018-08-02 |
2021-03-16 |
台湾微脂体股份有限公司 |
含有治疗抑郁症或焦虑症的治疗剂的缓释组合物及其用途
|
|
US20200038420A1
(en)
|
2018-08-03 |
2020-02-06 |
Enterin, Inc. |
Aminosterol compositions and methods of using the same for treating depression
|
|
US11154537B2
(en)
|
2018-08-10 |
2021-10-26 |
Eleusis Therapeutics Us, Inc. |
Method of treatment for ketamine infusion
|
|
WO2020041329A1
(en)
|
2018-08-20 |
2020-02-27 |
Yale University |
Combination therapy for treating or preventing depression or other mood diseases
|
|
PL3628313T3
(pl)
|
2018-09-28 |
2025-06-23 |
Novohale Therapeutics, Llc |
Kompozycja ketaminy do zastosowania w sposobie leczenia depresji przez podawanie dopłucne
|
|
US20210113494A1
(en)
|
2018-10-05 |
2021-04-22 |
Clexio Biosciences Ltd. |
Method Of Treating Post-Traumatic Stress Syndrome
|
|
US20210308040A1
(en)
|
2018-10-26 |
2021-10-07 |
Guangzhou Dazhou Biomedicine Ltd. |
Ketamine oral transmucosal delivery system
|
|
US20220000805A1
(en)
|
2018-10-29 |
2022-01-06 |
Hadas It Medical Research Services & Development Limited |
Combination of m-opioid receptor (mor) modulators for preventing and treating pain, suicidality and mental disorders
|
|
JP2022514194A
(ja)
|
2018-11-21 |
2022-02-10 |
セルテゴ セラピューティクス インコーポレイテッド |
自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
|
|
HRP20240255T1
(hr)
|
2019-01-11 |
2024-05-24 |
Alar Pharmaceuticals Inc. |
Ketamin pamoat i njegova uporaba
|
|
SG11202107994TA
(en)
|
2019-01-23 |
2021-08-30 |
Univ Michigan Regents |
Pharmacogenomic decision support for modulators of the nmda, glycine, and ampa receptors
|
|
WO2020168213A1
(en)
|
2019-02-15 |
2020-08-20 |
Massachusetts Institute Of Technology |
Methods for evaluating treatments and physiology in human patients using intravenous alpha-2 adrenergic antagonist agents
|
|
AU2020231172A1
(en)
|
2019-03-05 |
2021-09-23 |
Janssen Pharmaceuticals, Inc. |
Esketamine for the treatment of depression
|
|
AU2020231231A1
(en)
|
2019-03-07 |
2021-10-07 |
Arbormentis LLC |
Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
|
|
US20220143147A1
(en)
|
2019-03-18 |
2022-05-12 |
New York Medical College |
Intranasal neuropeptides for use in stress-related impairments
|
|
WO2020212596A1
(en)
|
2019-04-17 |
2020-10-22 |
Lts Lohmann Therapie-Systeme Ag |
Transdermal therapeutic system
|
|
WO2020223701A1
(en)
|
2019-05-02 |
2020-11-05 |
The Broad Institute, Inc. |
Methods for treating neurodevelopmental disorders
|
|
US20220202742A1
(en)
|
2019-05-07 |
2022-06-30 |
Clexio Biosciences Ltd. |
Dosage forms for preventing drug-facilitated assault
|
|
US20220062200A1
(en)
|
2019-05-07 |
2022-03-03 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
|
PL3976145T3
(pl)
|
2019-05-31 |
2025-04-28 |
Celon Pharma S.A. |
Inhalator do elektronicznie nadzorowanego pozajelitowego podawania kompozycji farmaceutycznej
|
|
EP3977469A1
(en)
|
2019-05-31 |
2022-04-06 |
Celon Pharma S.A. |
Electronically supervised administration of a pharmaceutical composition
|
|
WO2020247615A1
(en)
|
2019-06-04 |
2020-12-10 |
Sermone Sandra |
Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions
|
|
US20220151955A1
(en)
|
2019-08-05 |
2022-05-19 |
The Ketamine Research Foundation |
Ketamine for the treatment of postpartum symptoms and disorders
|
|
CN114286674A
(zh)
|
2019-08-28 |
2022-04-05 |
杨森制药公司 |
用于治疗患有包括自杀倾向在内的重性抑郁障碍的患者的艾司氯胺酮
|
|
GB201912505D0
(en)
|
2019-08-30 |
2019-10-16 |
Klaria Pharma Holding Ab |
Pharmaceutical formulation
|
|
AU2020345050A1
(en)
|
2019-09-13 |
2021-09-16 |
Janssen Pharmaceuticals, Inc. |
Intranasal administration of esketamine
|
|
EP4041226A1
(en)
|
2019-10-02 |
2022-08-17 |
Praxis Precision Medicines, Inc. |
Combinations of gaba-a receptor positive allosteric modulators and nmda antagonists, nmda negative allosteric modulators or nmda partial agonists
|
|
US20230095907A1
(en)
|
2019-10-18 |
2023-03-30 |
Institute Of Science And Technology Austria |
Stimulation of neuronal plasticity
|
|
WO2021087258A1
(en)
|
2019-10-31 |
2021-05-06 |
The Trustees Of Indiana University |
Compositions and methods for treating alcohol use disorder or a related condition thereof
|
|
WO2021108801A2
(en)
|
2019-11-15 |
2021-06-03 |
Consegna Pharma, Inc. |
Long acting nmda antagonists
|
|
JP2023503271A
(ja)
|
2019-11-18 |
2023-01-27 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
（２ｒ，６ｒ）－ヒドロキシノルケタミンの塩、それらの結晶形、およびその製造方法
|
|
CA3158059A1
(en)
|
2019-11-19 |
2021-05-27 |
Paul Edward Stamets |
Tryptamine compositions for enhancing neurite outgrowth
|
|
TW202135787A
(zh)
|
2019-12-12 |
2021-10-01 |
比利時商健生藥品公司 |
艾氯胺酮調配物及製備與儲存的方法
|
|
PH12022550775A1
(en)
|
2019-12-20 |
2023-08-23 |
Alar Pharmaceuticals Inc |
Long-acting injectable formulations of ketamine pamoate salts
|
|
US12268658B2
(en)
|
2019-12-30 |
2025-04-08 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating major depressive disorder
|
|
US12478592B2
(en)
|
2019-12-30 |
2025-11-25 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
|
|
JP2023511370A
(ja)
|
2020-01-22 |
2023-03-17 |
シーロス セラピューティクス， インコーポレイテッド |
Ｎｍｄａ拮抗薬の副作用の低減
|
|
DE102020106115A1
(de)
|
2020-03-06 |
2021-09-09 |
Lts Lohmann Therapie-Systeme Ag |
Iontophoretische Zusammensetzung zur Verabreichung von S-Ketamin
|
|
WO2021207349A1
(en)
|
2020-04-07 |
2021-10-14 |
Joseph Habboushe |
Prevention and treatment of virial infections
|
|
EP4153549A2
(en)
|
2020-05-20 |
2023-03-29 |
Certego Therapeutics Inc. |
Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
|
|
AU2021285083A1
(en)
|
2020-06-02 |
2023-01-19 |
Ix Biopharma Limited |
Methods for treating major depressive disorder and treatment-resistant depression
|
|
WO2021255522A1
(en)
|
2020-06-19 |
2021-12-23 |
Guangzhou Dazhou Biomedicine Ltd. |
Transdermal drug delivery system for ketamine
|
|
US20210401774A1
(en)
|
2020-06-27 |
2021-12-30 |
Robert Brent Turnipseed |
Ketamine protocols and data evaluation for treatment-resistant depression and trauma
|
|
US20220001014A1
(en)
|
2020-07-01 |
2022-01-06 |
Lida Ghaderi |
Compositions and methods for inducing biological mimicry in a mammal for the prevention and/or treatment of covid-19 and other diseases
|
|
US20220040106A1
(en)
|
2020-08-05 |
2022-02-10 |
Thomas Malcolm |
Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
|
|
EP3949956A1
(en)
|
2020-08-06 |
2022-02-09 |
LTS Lohmann Therapie-Systeme AG |
Esketamine-suspension-tts
|
|
CN115942935B
(zh)
|
2020-08-18 |
2025-09-05 |
奥克伍德实验室有限责任公司 |
包括氯胺酮的微球制剂及其制备和使用方法
|
|
WO2022081350A2
(en)
|
2020-09-30 |
2022-04-21 |
Duke University |
Methods for identification, stratification, and treatment of cns diseases
|
|
EP3995137B1
(de)
|
2020-11-09 |
2024-01-03 |
LTS Lohmann Therapie-Systeme AG |
Oraler dünnfilm
|
|
EP4247259A4
(en)
|
2020-11-18 |
2024-10-16 |
Indiana University Research and Technology Corporation |
METHODS FOR OBJECTIVE ASSESSMENT, RISK PREDICTION, ADAPTATION TO EXISTING MEDICATIONS AND NEW MEDICATION USE METHODS AND MONITORING RESPONSES TO TREATMENTS FOR MOOD DISORDERS
|
|
US11382873B1
(en)
|
2021-01-08 |
2022-07-12 |
Vitalis Analgesics LLC |
Oral administration of ketamine
|
|
IL282188A
(en)
|
2021-04-08 |
2022-11-01 |
Yeda Res & Dev |
Combined use of ketamine and bretigabine for the treatment of psychiatric disorders
|
|
JP7737544B2
(ja)
|
2021-08-13 |
2025-09-10 |
エックスダブリューファーマ リミテッド |
ケタミン誘導体の医薬組成物及び経口剤形
|
|
WO2023081109A1
(en)
|
2021-11-05 |
2023-05-11 |
Malcolm Thomas |
Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
|
|
WO2024010935A1
(en)
|
2022-07-07 |
2024-01-11 |
Vitalis Analgesics LLC |
Compositions of aspirin and ketamine
|